Perfusion apparatus and methods for pharmaceutical delivery
AssigneeBiostratum Incorporation
InventorsKarl Tryggvason, Olavi Lukkarinen, Pirkko Heikkilä, Teija Parpala
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and devices for the delivery of pharmaceuticals to target tissues in situ, in vivo, ex vivo, or in vitro. In particular, the methods and devices relate to contacting a target tissue with a pharmaceutical in a re-circulating, oxygenated perfusate solution to provide for effective delivery of the pharmaceutical to the target tissue.
Claims12
An improved method for gene therapy of kidney disorders, wherein the gene therapy comprises contacting the kidney of a patient with a kidney disorder with an amount effective for treatment of the disorder of a viral vector gene therapy pharmaceutical for treatment of the disorder, wherein the improvement comprises contacting the patient's kidney with the viral vector gene therapy pharmaceutical in a re-circulating, oxygenated perfusate solution, and where the perfusate solution is held at about 37° C., such that there is effective delivery of the viral vector gene therapy pharmaceutical.
A method for the extended delivery of a pharmaceutical to mammalian kidney tissue comprising contacting the mammalian kidney tissue with the pharmaceutical in a re-circulating, oxygenated perfusate, where the perfusate solution is held at about 37° C., such that there is effective delivery of the viral vector gene therapy pharmaceutical.
A method for the effective delivery of a viral vector gene therapy pharmaceutical to a mammalian kidney tissue comprising contacting the mammalian kidney tissue with the viral vector gene therapy pharmaceutical in a re-circulating, oxygenated perfusate solution, where the solution is held at about 37° C., such that there is effective delivery of the viral vector gene therapy pharmaceutical.
An improved method for gene therapy of kidney disorders, wherein the gene therapy comprises contacting the lung of a patient with a kidney disorder with an amount effective for treatment of the disorder of a gene therapy pharmaceuticals for treatment of the disorder, wherein the improvement comprises contacting the patient's kidney with the gene therapy pharmaceutical in a re-circulating, oxygenated perfusate solution, and where the perfusate solution is held at about 37° C., such that there is effective delivery of the viral vector gene therapy pharmaceutical.
Dependencies are inferred from the claim text.